Open Access

Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma

  • Gerald N DeLorenze1Email author,
  • Lucie McCoy2,
  • Ai-Lin Tsai1,
  • Charles P QuesenberryJr1,
  • Terri Rice2,
  • Dora Il'yasova3 and
  • Margaret Wrensch2
Contributed equally
BMC Cancer201010:215

DOI: 10.1186/1471-2407-10-215

Received: 29 August 2009

Accepted: 19 May 2010

Published: 19 May 2010

Abstract

Background

Malignant glioma is a rare cancer with poor survival. The influence of diet and antioxidant intake on glioma survival is not well understood. The current study examines the association between antioxidant intake and survival after glioma diagnosis.

Methods

Adult patients diagnosed with malignant glioma during 1991-1994 and 1997-2001 were enrolled in a population-based study. Diagnosis was confirmed by review of pathology specimens. A modified food-frequency questionnaire interview was completed by each glioma patient or a designated proxy. Intake of each food item was converted to grams consumed/day. From this nutrient database, 16 antioxidants, calcium, a total antioxidant index and 3 macronutrients were available for survival analysis. Cox regression estimated mortality hazard ratios associated with each nutrient and the antioxidant index adjusting for potential confounders. Nutrient values were categorized into tertiles. Models were stratified by histology (Grades II, III, and IV) and conducted for all (including proxy) subjects and for a subset of self-reported subjects.

Results

Geometric mean values for 11 fat-soluble and 6 water-soluble individual antioxidants, antioxidant index and 3 macronutrients were virtually the same when comparing all cases (n = 748) to self-reported cases only (n = 450). For patients diagnosed with Grade II and Grade III histology, moderate (915.8-2118.3 mcg) intake of fat-soluble lycopene was associated with poorer survival when compared to low intake (0.0-914.8 mcg), for self-reported cases only. High intake of vitamin E and moderate/high intake of secoisolariciresinol among Grade III patients indicated greater survival for all cases. In Grade IV patients, moderate/high intake of cryptoxanthin and high intake of secoisolariciresinol were associated with poorer survival among all cases. Among Grade II patients, moderate intake of water-soluble folate was associated with greater survival for all cases; high intake of vitamin C and genistein and the highest level of the antioxidant index were associated with poorer survival for all cases.

Conclusions

The associations observed in our study suggest that the influence of some antioxidants on survival following a diagnosis of malignant glioma are inconsistent and vary by histology group. Further research in a large sample of glioma patients is needed to confirm/refute our results.

Background

Mortality following diagnosis of malignant brain tumors varies by histologic type and other risk factors. Between 1991 and 2000, adults diagnosed with malignant glioma had median survival times that ranged from 7 months for highest grade tumors (gliomablastoma multiforme) to 91 months for lower grade tumors (oligodendroglioma) [1]. The majority of glioma patients are diagnosed with gliomablastoma multiforme (GBM), and 5-year survivorship is < 3%. Among patient characteristics that are associated with differential survival rates following a glioma diagnosis, only age appears to be as strong a predictor as histology [2]. Other risk factors such as tumor location and the magnitude of tumor resection [36], molecular and genetic markers [713], and Karnofsky performanace status [1420] have been examined in a number of studies of survival in glioma patients. However, the potential association of diet, in general, and antioxidant intake, in particular, with survival after glioma diagnosis in human populations has been only sparsely investigated [21, 22].

Oxygen-derived free radicals produced by lipid peroxidation are believed to play an important role in cancer development [23, 24]. Antioxidants can act as reducing agents to prevent oxidative reactions by either scavenging reactive oxygen species (ROS) or inhibiting cellular signaling enzymes such as protein kinase C (PKC) [25, 26]. Proliferation of malignant gliomas can be induced by PKC isoforms through several signaling pathways [2730]. Endogenous antioxidant enzymes are one of the brain's natural defense mechanisms to remove the highly toxic hydrogen peroxide molecule; decreased activity of glutathione peroxidase and reductase have been found in glioblastoma tissue [3133]. Dietary antioxidants, including isoflavones and polyphenols, have been shown in laboratory studies to enhance growth restriction of cancer cells in general [34] and glioma cells in particular [35, 36]. However other studies have indicated that high concentrations of non-enzymatic antioxidants, including carotenoids and flavonoids, can exhibit pro-oxidant behavior, particularly in the presence of redox-active metals (copper, iron) and a high pH [26, 37]. There is also evidence that the combination of cigarette smoking and antioxidant intake can diminish the effects of radiotherapy for certain cancers [38].

With respect to a potential effect of antioxidants on survival of patients with gliomas, two opposing hypotheses can be formulated. First, because brain tissues are one of the most oxidative environments and therefore susceptible to radiation damage, antioxidants may protect normal brain tissues from radiation damage and lead to better survival [39]. On the other hand, antioxidants may make the glioma more resistant to tumor killing by radiation [40], possibly leading to poorer patient survival. Given this lack of consensus it is important then to examine the potential association between antioxidant intake and patient survival in a large population-based cohort of adults diagnosed with malignant glioma.

In the current study, we examine patterns of survival after a diagnosis of malignant glioma in relation to intake of dietary antioxidants and other nutrients. We estimate the contribution of antioxidants and other nurtients, both separately and in combination with each other, to glioma survival adjusting for known risk factors and confounders. Our results are stratified by histology group and by type of interview, i.e. patient self-report or interview with the patient's designated proxy.

Methods

Study population

The ascertainment of glioma cases and study subject eligibility requirements have been described in detail by Wiemels et al. [41] and Wrensch et al. [42]. In summary, any adult (ages ≥ 20) with an incident diagnosis of glioma (ICD-O morphology codes 9380-9481) between August 1991 and April 1994 (series 1) and May 1997 and August 1999 (series 2) residing anywhere in the six county San Francisco-Oakland MRSA ould meet study eligibility criteria [1]. Potential glioma cases were identified using rapid case ascertainment (RCA) provided by a Surveillance Epidemiology and End Results (SEER) participating registry, the Northern California Cancer Center (NCCC). Subjects or their designated proxies provided written consent to obtain and review pathology specimens and records to confirm a glioma diagnosis. Consenting patients or their proxies completed surveys concerning a number of characteristics and potential risk factors. Other glioma cases were not included as study subjects because either consent was not obtained, neuropathology review was not possible or revealed a diagnosis not eligible for the study.

Neuropathology Review

Pathology records and specimens, provided by the diagnosing hospitals, were reviewed by a neuropathologist [43]. WHO criteria [44] were used to classify all tumors. GBM corresponds to WHO grade IV, anaplastic astrocytoma (AA) to WHO grade III, and astrocytoma to WHO grade II.

Determination of Vital Status

NCCC-SEER, which routinely ascertains vital status via California State mortality tapes and the National Death Index, provided vital status for the study subjects in December 2002 [1]. For cases not known to be deceased, a letter was sent to the last known address, followed by a telephone call. Mortality was updated from SEER in December, 2008. For a small number of cases who could not be located, date of last contact (as determined by NCCC-SEER) was used. Patients not known to be dead were censored at date of last contact.

Dietary questionnaires and interviews

Series I

Eligible cases or designated proxies were given an in-person interview at the subjects' home or other location of their choice [45]. Subjects received a dietary questionnaire in advance, which was collected or completed at the in-person interview. The temporal period for all questions was the year preceding the glioma diagnosis.

A detailed description of the Series I questionnaire has been provided in Tedeschi-Blok et al [46]. Briefly, a 79-item food-frequency questionnaire was modified from the US National Cancer Institutes' (Block's) Health Habits and History Questionnaire [47]and the Los Angeles Glioma and Meningioma Study Questionnaire [48]. Subjects reported their usual frequencies of consumption of each food item. The frequency choices included: 'never', 'less than 1 per month', '1 per month', '2-3 per month', '1 per week', '2 per week', '3-4 per week', '5-6 per week', '1 per day', and '2 or more per day'. Portion sizes were not asked, but were estimated using gender- and age- specific values from the Block and colleagues' National Cancer Institute's Health Habits and History Questionnaire [47].

Series II

Series II eligible cases or designated proxies were approached in a manner similar to Series I. However instead of receiving a self-administered diet questionnaire in advance, interviewers asked the diet questions in Series II. The 96-item Series II diet questionnaire was modified from the US National Cancer Institutes' (Block's) Health Habits and History Questionnaire. Modifications [47]. The frequency choices included: 'never or less than 1 per month', '1 per month', '2-3 per month, '1 per week', '2 per week', '3-4 per week', '5-6 per week', '1 per day'.

Series I & II

For eligible subjects who did not wish to participate in the full interview, a 5-minute phone interview was administered using an abbreviated questionnaire asking basic demographic and dietary questions. This permitted evaluation of major differences in dietary consumption between those cases who participated in the full interview and those who did not.

Dietary analyses

Assignment of reported food frequency choices into levels of specific nutrients has been previously described in detail by Tedeschi-Blok et al [46]. Intake of each food item was converted to grams consumed per day by applying an appropriate algorithm for each series. For both series, a nutrient database included a total of 27 nutrients per 100 grams for each food item. Of the 27 nutrients, 16 antioxidants plus calcium and 3 macronutrients were available for our survival analysis. A total daily antioxidant index intake was calculated by summing the product of grams consumed over all food items and units of antioxidant index per gram from an antioxidant index database for fruit, vegetable, juice and tea food items [4951]. Antioxidant index values were units of micromoles Trolox equivalents per gram of food. Trolox equivalents per gram of food were measured by the oxygen radical absorbance capacity (ORAC) assay [50, 51].

Use of Alcohol and Tobacco

The Series I and II surveys included questions concerning alcohol consumption (age at first drink; weekly consumption of wine, beer and liquor) and cigarette smoking (age began smoking; number of cigarettes per day; number of years of active smoking). Because both alcohol and cigarette smoke are oxidants and have been shown to be related to oxidative stress in the brain and the expression of antioxidants (e.g., vitamin C and beta-carotene) [52, 53], responses to these questions were included in the study analyses.

Determination of Treatment Information

Treatment information and other clinical characteristics was obtained from NCCC-SEER, medical record abstraction, and a clinical trials database from UCSF. NCCC-SEER treatment information includes summary data for surgery, radiation, and chemotherapy. NCCC-SEER provided a summary of curative treatment information given as the first course of therapy following diagnosis. Information from medical record abstraction included Karnofsky performance status (KPS) at time of diagnosis, tumor location, surgical resection, radiation, and chemotherapy. The UCSF Neuro-Oncology Service database contained these data items for patients entered in clinical trials. Since KPS was not available for many subjects, it was not included in these analyses.

Statistical Analysis

Preliminary data analysis included an examination of the univariate distributions of nutrients and potential confounders including patient demographics (age, gender, race, education, income, marital status), histology group, treatment, series, comorbid conditions (epilepsy, chicken pox, shingles, allergies), Karnofsky score, alcohol and tobacco use for all glioma cases (including interviews completed by a designated proxy) and for only cases who were interviewed directly (no proxy). Several of these potential confounders, age at diagnosis in particular, have been previously reported as significantly associated with mortality following a glioma diagnosis in a survival analysis of the same patients included in the current study [1]. Descriptive statistics included geometric mean nutrient intake (given the skewness in nutrient distributions) adjusted for total calories. Adjusted geometric means were obtained via a linear regression of log nutrient on calories and calculating the anti-log of the least squares mean. Preliminary analyses also included an examination of each nutrient and potential confounder in relation to survival via Kaplan-Meier survival curves and log-rank tests.

Based upon the results of the univariate analyses, Cox proportional hazards models were used for point and interval estimation of mortality hazard ratios associated with each antioxidant, antioxidant index, and other nutrients adjusting for potential confounders. Regression analyses were stratified by grade and conducted using all (including proxy interviews) glioma cases and in the subset of self-reported cases. Primary analyses examined nutrients categorized in tertiles to allow examination of dose response and threshold effects. Given previous studies in this and other cohorts [1, 36, 15, 54], age and treatment (radiation, chemotherapy, surgery: all as dichotomous yes/no) were a priori included in all regression analyses. As is standard in analyses of nutrients in relation to health outcomes, total caloric intake was also a priori included in all regression models. Given results from our preliminary analyses as well as evidence from previous studies of risk factors [38, 41, 45] associated with malignant glioma, education, marital status, alcohol (age at first alcoholic drink) and tobacco use (pack years of cigarette smoking) were included as covariates in the regression analysis. In addition, for any significant base-model adjusted nutrient survival associations that were observed, we did a check for other potential confounders (e.g. income, comorbid conditions, protein intake), although none were found to appreciably change hazard ratio (HR) estimates. All tests of significance in this analysis were 2-sided, and all statistical analyses were completed using SAS statistical software (Version 9.1, Cary, NC). Final models were selected based upon statistical significance.

Results

The distribution of demographic, clinical and behaviorial characteristics is presented in Table 1, which is stratified for all cases (including interviews completed by proxy) and for self-reported cases (case was interviewed) only. Self-reported (SR) cases were somewhat younger in age at the time of diagnosis when compared to all cases. The distribution of gender and race categories was similar in both groups. Self-reported cases were more likely to have completed at least one year of college, had a higher proportion of Grade II (histology) tumors, and a lower proportion of Grade IV tumors in comparison to all cases. Both groups showed similar distributions in the categories for age at first alcoholic drink and smoking (pack-years). For glioma-related treatment the self-reported cases had somewhat higher rates of receiving surgical resection, radiotherapy and chemotherapy when compared to all cases.
Table 1

Distribution of patient characteristics; San Francisco Bay Area Adult Glioma Study, 1991-2000

Characteristics

All cases (N = 748)

Self-reported cases (N = 450)

Age (median ± SE)

55.7 ± 0.6

49.8 ± 0.7

Gender (% male)

57.1%

59.1%

Ethnicity (% White)

83.4%

84.2%

Education

  

   < 12 years

12.2%

6.4%

   High school graduate

24.2%

20.9%

   ≥ 1 year college

63.6%

72.7%

Histology Group

  

   Grade II

19.1%

28.2%

   Grade III

17.4%

19.3%

   Grade IV*

63.5%

52.4%

Treatment

  

   Surgical Resection

83.0%

91.8%

   Radiotherapy

73.7%

83.1%

   Chemotherapy

20.3%

26.9%

Age at first drink

  

   Never drank alcohol

9.2%

8.0%

   <18 years old

30.4%

31.3%

   18 - 20 years old

33.2%

34.7%

   ≥21 years old

26.6%

26.0%

   Unknown

0.7%

0%

Total Packyears

  

   Never smoked

43.5%

46.0%

   > 0 to ≤ 18.5

25.4%

30.0%

   > 18.5

25.9%

22.0%

   Unknown

5.2%

2.0%

includes 44 astrocytomas, 63 oligodendrogliomas, 36 oligoastrocytomas.

includes 90 astrocytomas, 26 oligodendrogliomas, 14 oligoastrocytomas.

*all (n = 475) glioblastomas.

Geometric means of the total daily antioxidants and other nutrients consumed adjusted for total calories among all cases are shown in Table 2. The geometric mean values for the Antioxidant Index are virtually the same when comparing all cases to self-reported cases only. A similar pattern is observed for most of the 11 fat-soluble and 7 water-soluble individual antioxidants and the 3 macronutrients listed in Table 2.
Table 2

Antioxidant and nutrient geometric mean values (adjusted for total calorie intake)

Nutrient

All cases (N = 748)

Self-reported cases (N = 450)

Fat-soluble:

  

   Vitamin E (mg)

7.8

7.6

   Carotenoids (mcg)

3441.1

3327.4

   Alpha-carotene (mcg)

589.9

554.8

   Beta-carotene (mcg)

2783.5

2696.4

   Lutein (mcg)

1889.5

1906.2

   Lycopene (mcg)

1230.0

1277.1

   Cryptoxanthin (mcg)

104.6

110.2

   Coumestrol (mcg)

107.7

111.3

   Matairesinol (mcg)

23.4

23.6

   Secoisolariciresinol (mcg)

105.9

105.4

   Linoleic acid (g)

11.2

10.9

Water-soluble:

  

   Vitamin C (mg)

107.5

108.6

   Formononetin (mcg)

14.3

15.2

   Genistein (mcg)

230.8

248.3

   Daidzein (mcg)

352.1

370.8

   Biochanin A (mcg)

22.8

23.4

   Calcium (mg)

642.6

626.3

   Folate (mcg)

359.7

355.9

Antioxidant index

2442.9

2445.8

Macronutrients:

  

   Total Protein (g)

59.8

58.6

   Total Fat (g)

58.3

56.0

   Total Cholesterol (mg)

210.4

202.8

Total Kcal (unadjusted)

1634.0

1599.8

Hazard ratios for tertiles of daily intake of fat-soluble antioxidants adjusted for age at glioma diagnosis, education, marital status, treatment, cigarette smoking (pack-years), alcohol (age at first alcoholic drink), and total calories, stratified by proxy status (all cases vs self-reported cases only) and histology group (Grade II, III, and IV) are presented in Table 3. Examining these results for those that were statistically significant, we found that the hazard ratio for moderate intake of lycopene (HR = 2.31, 95% CI = 1.12 to 4.75, for second tertile compared to lowest tertile, in self-reported cases only) was elevated within the Grade II histology group. Similarly moderate intake of lycopene among patients in the Grade III histology group was associated with poorer survival. Hazard ratios for high intake of vitamin E (HR = 0.37, 95% CI = 0.17 to 0.81, highest tertile compared to lowest tertile, in all cases) and for both moderate and high intake of secoisolariciresinol (for second tertile and for highest tertile compared to lowest tertile, in all cases) among Grade III patients indicate enhanced survival. Moderate intake of alpha-carotene (HR = 2.12, 95% CI = 1.08 to 4.18, for second tertile compared to lowest tertile, in self-reported cases only) among Grade III patients was associated with poorer survival. In the Grade IV histology group, moderate to high intake of cryptoxanthin (for second tertile and for highest tertile compared to lowest tertile, in all cases), moderate intake of matairesonal (for second tertile compared to lowest tertile, in all cases), and high intake of secoisolariciresinol (for highest tertile compared to lowest tertile, in all cases) was associated with poorer survival.
Table 3

Associations between intake of fat-soluble antioxidants and survival following glioma diagnosis, stratified by histology group

Nutrient (unit) Tertiles

All or self-report (SR) only

Grade II

Grade III

Grade IV

     

(143 cases, 72 deaths)

(130 cases, 103 deaths)

(475 cases, 473 deaths)

 

Lower limit

 

Upper limit

 

HR

95% CI

HR

95% CI

HR

95% CI

Vitamin E (mg)

T1:

0.8

to

6.4

ALL

1

 

1

 

1

 

T2:

6.5

to

9.4

 

1.00

(0.44-2.27)

1.02

(0.60-1.74)

1.15

(0.89-1.50)

T3:

9.5

to

42.1

 

1.05

(0.33-3.33)

0.37*

(0.17-0.81)

0.81

(0.58-1.12)

T1:

0.8

to

6.4

SR

1

 

1

 

1

 

T2:

6.5

to

9.4

 

0.87

(0.38-2.01)

1.75

(0.83-3.69)

1.06

(0.74-1.53)

T3:

9.5

to

42.1

 

0.82

(0.23-2.95)

1.06

(0.38-2.98)

0.97

(0.62-1.51)

Alpha-carotene (mcg)

       

T1:

7.4

to

427.1

ALL

1

 

1

 

1

 

T2:

428.6

to

916.1

 

0.64

(0.29-1.40)

1.44

(0.81-2.56)

0.99

(0.76-1.28)

T3:

917.8

to

17008.2

 

1.10

(0.55-2.22)

0.91

(0.48-1.72)

1.06

(0.80-1.40)

T1:

7.4

to

427.1

SR

1

 

1

 

1

 

T2:

428.6

to

916.1

 

0.65

(0.28-1.53)

.12*

(1.08-4.18)

0.88

(0.60-1.27)

T3:

917.8

to

17008.2

 

1.20

(0.57-2.53)

1.18

(0.57-2.45)

1.18

(0.81-1.72)

Beta-carotene (mcg)

       

T1:

257.7

to

2070.1

ALL

1

 

1

 

1

 

T2:

2070.2

to

3754.1

 

0.86

(0.43-1.74)

0.95

(0.54-1.68)

1.08

(0.84-1.39)

T3:

3757.6

to

39807.1

 

0.92

(0.45-1.90)

0.76

(0.37-1.54)

1.11

(0.85-1.46)

T1:

257.7

to

2070.1

SR

1

 

1

 

1

 

T2:

2070.2

to

3754.1

 

0.79

(0.36-1.71)

1.36

(0.64-2.90)

1.06

(0.74-1.53)

T3:

3757.6

to

39807.1

 

1.08

(0.53-2.21)

1.45

(0.61-3.48)

0.97

(0.66-1.41)

Carotenoids (mcg)

       

T1:

303.0

to

2501.5

ALL

1

 

1

 

1

 

T2:

2503.5

to

4658.0

 

0.89

(0.43-1.84)

1.05

(0.60-1.82)

1.11

(0.87-1.43)

T3:

4662.2

to

51458.1

 

0.91

(0.46-1.82)

0.68

(0.33-1.41)

1.18

(0.89-1.55)

T1:

303.0

to

2501.5

SR

1

 

1

 

1

 

T2:

2503.5

to

4658.0

 

0.74

(0.34-1.64)

1.70

(0.84-3.46)

1.13

(0.78-1.63)

T3:

4662.2

to

51458.1

 

1.02

(0.50-2.06)

1.21

(0.50-2.90)

1.02

(0.69-1.50)

Lutein (mcg)

       

T1:

31.3

to

1285.5

ALL

1

 

1

 

1

 

T2:

1288.6

to

2687.6

 

0.69

(0.36-1.35)

0.60

(0.35-1.02)

0.96

(0.74-1.23)

T3:

2694.2

to

51290.4

 

0.56

(0.26-1.18)

1.03

(0.53-2.01)

1.19

(0.92-1.53)

T1:

31.3

to

1285.5

SR

1

 

1

 

1

 

T2:

1288.6

to

2687.6

 

0.70

(0.35-1.43)

1.11

(0.55-2.26)

1.06

(0.73-1.53)

T3:

2694.2

to

51290.4

 

0.65

(0.30-1.41)

1.86

(0.72-4.78)

1.07

(0.74-1.53)

Lycopene (mcg)

       

T1:

0.0

to

914.8

ALL

1

 

1

 

1

 

T2:

915.8

to

2118.3

 

1.78

(0.92-3.46)

1.33

(0.77-2.31)

1.27

(0.99-1.62)

T3:

2121.5

to

26788.8

 

0.81

(0.37-1.80)

0.70

(0.36-1.36)

1.10

(0.85-1.44)

T1:

0.0

to

914.8

SR

1

 

1

 

1

 

T2:

915.8

to

2118.3

 

2.31*

(1.12-4.75)

2.17*

(1.02-4.62)

1.10

(0.77-1.57)

T3:

2121.5

to

26788.8

 

1.00

(0.41-2.44)

2.31

(0.98-5.43)

1.00

(0.69-1.44)

Cryptoxanthin (mcg)

       

T1:

0.0

to

79.8

ALL

1

 

1

 

1

 

T2:

80.2

to

180.3

 

1.52

(0.70-3.29)

0.66

(0.37-1.18)

1.34*

(1.04-1.73)

T3:

180.4

to

1437.2

 

0.92

(0.39-2.17)

1.24

(0.66-2.33)

1.57*

(1.20-2.06)

T1:

0.0

to

79.8

SR

1

 

1

 

1

 

T2:

80.2

to

180.3

 

1.83

(0.86-3.92)

1.04

(0.51-2.14)

1.19

(0.82-1.72)

T3:

180.4

to

1437.2

 

0.85

(0.35-2.08)

1.14

(0.52-2.51)

1.32

(0.90-1.93)

Coumestrol (mcg)

       

T1:

3.0

to

83.4

ALL

1

 

1

 

1

 

T2:

84.1

to

145.3

 

0.99

(0.51-1.90)

0.70

(0.38-1.30)

1.13

(0.88-1.45)

T3:

145.5

to

1315.3

 

0.77

(0.33-1.75)

1.06

(0.60-1.87)

1.16

(0.88-1.54)

T1:

3.0

to

83.4

SR

1

 

1

 

1

 

T2:

84.1

to

145.3

 

1.11

(0.56-2.21)

1.41

(0.67-2.96)

0.98

(0.68-1.40)

T3:

145.5

to

1315.3

 

0.73

(0.29-1.82)

0.96

(0.45-2.05)

1.06

(0.72-1.57)

Matairesinol (mcg)

       

T1:

0.1

to

17.6

ALL

1

 

1

 

1

 

T2:

17.7

to

34.5

 

1.17

(0.55-2.49)

0.88

(0.51-1.52)

1.38*

(1.08-1.77)

T3:

34.6

to

218.6

 

0.78

(0.36-1.69)

0.86

(0.48-1.54)

1.20

(0.92-1.57)

T1:

0.1

to

17.6

SR

1

 

1

 

1

 

T2:

17.7

to

34.5

 

1.14

(0.52-2.50)

1.27

(0.59-2.73)

1.34

(0.95-1.89)

T3:

34.6

to

218.6

 

0.88

(0.38-2.04)

1.00

(0.48-2.09)

1.07

(0.74-1.55)

Secoisolariciresinol (mcg)

       

T1:

6.3

to

87.3

ALL

1

 

1

 

1

 

T2:

87.4

to

146.0

 

1.25

(0.60-2.61)

0.54*

(0.31-0.93)

1.04

(0.81-1.33)

T3:

146.1

to

698.4

 

1.95

(0.93-4.10)

0.48*

(0.25-0.92)

1.32*

(1.02-1.72)

T1:

6.3

to

87.3

SR

1

 

1

 

1

 

T2:

87.4

to

146.0

 

1.19

(0.52-2.73)

0.75

(0.38-1.49)

0.83

(0.58-1.21)

T3:

146.1

to

698.4

 

1.41

(0.63-3.15)

0.51

(0.22-1.19)

0.95

(0.66-1.36)

Linoleic acid (g)

       

T1:

1.6

to

8.9

ALL

1

 

1

 

1

 

T2:

9.0

to

14.6

 

1.21

(0.57-2.58)

1.15

(0.66-2.02)

1.03

(0.80-1.32)

T3:

14.7

to

57.7

 

0.95

(0.35-2.60)

0.50

(0.25-1.01)

0.87

(0.63-1.19)

T1:

1.6

to

8.9

SR

1

 

1

 

1

 

T2:

9.0

to

14.6

 

1.14

(0.51-2.53)

0.88

(0.41-1.89)

0.85

(0.60-1.21)

T3:

14.7

to

57.7

 

1.17

(0.41-3.35)

0.59

(0.23-1.52)

0.96

(0.60-1.54)

adjusted for reporting status (all cases vs self reported cases only), age at diagnosis (<48,48-65,>65), treatment (radiation, chemo, surgery - yes/no), education (<12, 12, >12), marital status (yes/no), total calories (continuous), pack years (median = 18.5), and age at first alcoholic drink (<18,18-20,>20).

* p < 0.05

Table 4 presents hazard ratios for tertiles of daily intake of water-soluble antioxidants adjusted for the same set of covariates as the models shown in Table 3. Among Grade II patients, moderate intake of folate was associated with enhanced survival (HR = 0.45, 95% CI = 0.20 to 0.99, for second tertile compared to lowest tertile, in all cases). Moderate intake of formonoetin among Grade III patients was also associated with enhanced survival. Among Grade IV patients, high intake of vitamin C and genistein as well as moderate intake of formonoetin, in all cases, was associated with poorer survival.
Table 4

Associations between intake of water-soluble antioxidants and survival following glioma diagnosis, stratified by histology group

Nutrient (unit) Tertiles

All or self-report (SR) only

Grade II

Grade III

Grade IV

     

(143 cases, 72 deaths)

(130 cases, 103 deaths)

(475 cases, 473 deaths)

 

Lower limit

 

Upper limit

 

HR

95% CI

HR

95% CI

HR

95% CI

Vitamin C (mg)

       

T1:

4.5

to

84.1

ALL

1

 

1

 

1

 

T2:

84.1

to

149.6

 

1.33

(0.72-2.48)

0.71

(0.40-1.27)

1.23

(0.96-1.57)

T3:

149.6

to

869.6

 

0.52

(0.23-1.20)

1.07

(0.56-2.03)

.44*

(1.09-1.91)

T1:

4.5

to

84.1

SR

1

 

1

 

1

 

T2:

84.1

to

149.6

 

1.21

(0.63-2.34)

1.04

(0.50-2.16)

1.2

(0.84-1.72)

T3:

149.6

to

869.6

 

0.56

(0.21-1.47)

1.18

(0.51-2.75)

1.28

(0.87-1.90)

Formononetin (mcg)

       

T1:

0.1

to

9.3

ALL

1

 

1

 

1

 

T2:

9.4

to

23.0

 

1.08

(0.55-2.15)

47*

(0.25-0.89)

.27*

(1.00-1.61)

T3:

23.1

to

155.6

 

1.08

(0.46-2.52)

0.79

(0.43-1.43)

1.04

(0.79-1.37)

T1:

0.1

to

9.3

SR

1

 

1

 

1

 

T2:

9.4

to

23.0

 

1.18

(0.57-2.42)

0.67

(0.29-1.53)

1.16

(0.82-1.63)

T3:

23.1

to

155.6

 

0.96

(0.41-2.29)

0.56

(0.27-1.14)

1.03

(0.71-1.49)

Genistein (mcg)

       

T1:

8.1

to

141.3

ALL

1

 

1

 

1

 

T2:

141.7

to

291.3

 

1.18

(0.57-2.43)

1.18

(0.66-2.12)

1.2

(0.92-1.56)

T3:

291.6

to

44265.2

 

1.05

(0.40-2.74)

1.25

(0.69-2.27)

1.35*

(1.00-1.81)

T1:

8.1

to

141.3

SR

1

 

1

 

1

 

T2:

141.7

to

291.3

 

0.93

(0.42-2.07)

1.53

(0.71-3.29)

1.02

(0.70-1.48)

T3:

291.6

to

44265.2

 

0.78

(0.29-2.15)

1.56

(0.65-3.74)

1.42

(0.96-2.10)

Daidzein (mcg)

       

T1:

10.1

to

269.0

ALL

1

 

1

 

1

 

T2:

270.1

to

440.6

 

1.77

(0.96-3.26)

0.71

(0.40-1.28)

1.06

(0.83-1.36)

T3:

440.6

to

36886.6

 

1.7

(0.70-4.14)

1.01

(0.55-1.85)

1.13

(0.86-1.49)

T1:

10.1

to

269.0

SR

1

 

1

 

1

 

T2:

270.1

to

440.6

 

1.54

(0.75-3.17)

1.05

(0.49-2.25)

1.2

(0.84-1.72)

T3:

440.6

to

36886.6

 

1.21

(0.46-3.20)

0.7

(0.29-1.66)

1.08

(0.75-1.57)

Biochanin A (mcg)

       

T1:

0.0

to

15.4

ALL

1

 

1

 

1

 

T2:

15.4

to

37.8

 

1.03

(0.53-2.01)

0.84

(0.47-1.51)

1.27

(0.99-1.62)

T3:

37.8

to

334.7

 

0.6

(0.28-1.30)

0.91

(0.45-1.88)

1.26

(0.97-1.64)

T1:

0.0

to

15.4

SR

1

 

1

 

1

 

T2:

15.4

to

37.8

 

1.24

(0.62-2.49)

0.56

(0.26-1.20)

0.92

(0.64-1.33)

T3:

37.8

to

334.7

 

0.56

(0.24-1.32)

0.66

(0.27-1.57)

1.02

(0.70-1.50)

Calcium (mg)

       

T1:

85.0

to

499.9

ALL

1

 

1

 

1

 

T2:

501.6

to

807.7

 

1.23

(0.61-2.47)

0.7

(0.39-1.24)

1.06

(0.82-1.37)

T3:

808.1

to

2686.8

 

0.95

(0.35-2.53)

1.22

(0.59-2.55)

0.87

(0.64-1.19)

T1:

85.0

to

499.9

SR

1

 

1

 

1

 

T2:

501.6

to

807.7

 

1.5

(0.70-3.24)

1.32

(0.65-2.67)

1.06

(0.74-1.52)

T3:

808.1

to

2686.8

 

1.56

(0.58-4.15)

2.27

(0.93-5.53)

0.81

(0.53-1.24)

Folate (mcg)

       

T1:

56.5

to

297.0

ALL

1

 

1

 

1

 

T2:

297.4

to

434.7

 

0.45*

(0.20-0.99)

1.05

(0.62-1.78)

0.84

(0.65-1.09)

T3:

435.1

to

1530.0

 

0.35

(0.12-1.01)

0.59

(0.28-1.24)

1.08

(0.78-1.50)

T1:

56.5

to

297.0

SR

1

 

1

 

1

 

T2:

297.4

to

434.7

 

0.49

(0.22-1.12)

1.29

(0.61-2.73)

0.82

(0.57-1.17)

T3:

435.1

to

1530.0

 

0.41

(0.13-1.29)

2.26

(0.77-6.60)

1.09

(0.68-1.74)

adjusted for reporting status (all cases vs self reported cases only), age at diagnosis (<48,48-65,>65), treatment (radiation, chemo, surgery - yes/no), education (<12, 12, >12), marital status (yes/no), total calories (continuous), pack years (median=18.5), and age at first alcoholic drink (<18,18 - 20,>20).

* p < 0.05

Hazard ratios for tertiles of the Antioxidant Index and the macronutrients are presented in Table 5.
Table 5

Associations of total antioxidant index and macronutrients with glioma survival, stratified by histology group

Nutrient (unit) Tertiles

All or self-report (SR) only

Grade II

Grade III

Grade IV

 

Lower limit

 

Upper limit

 

(143 cases, 72 deaths)

(130 cases, 103 deaths)

(475 cases, 473 deaths)

     

HR

95% CI

HR

95% CI

HR

95% CI

Antioxidant index

       

T1:

50.1

to

1961.9

ALL

1

 

1

 

1

 

T2:

1963.2

to

3263.0

 

1.34

(0.70-2.54)

1.31

(0.78-2.18)

1.02

(0.78-1.32)

T3:

3266.1

to

13512.6

 

0.67

(0.30-1.47)

1.04

(0.58-1.88)

0.36*

(1.02-1.81)

T1:

50.1

to

1961.9

SR

1

 

1

 

1

 

T2:

1963.2

to

3263.0

 

1.41

(0.71-2.80)

1.36

(0.62-2.94)

1.18

(0.82-1.68)

T3:

3266.1

to

13512.6

 

0.74

(0.31-1.77)

1.03

(0.49-2.16)

1.07

(0.72-1.59)

Total Protein (g)

       

T1:

11.4

to

49.5

ALL

1

 

1

 

1

 

T2:

49.6

to

70.8

 

0.44*

(0.20-0.95)

1.44

(0.75-2.74)

1.08

(0.83-1.40)

T3:

71.1

to

241.5

 

0.32

(0.10-1.04)

1.73

(0.78-3.83)

0.64*

(0.43-0.95)

T1:

11.4

to

49.5

SR

1

 

1

 

1

 

T2:

49.6

to

70.8

 

0.40*

(0.18-0.93)

1.57

(0.74-3.31)

1.13

(0.78-1.62)

T3:

71.1

to

241.5

 

0.53

(0.15-1.81)

1.18

(0.42-3.27)

0.88

(0.52-1.50)

Total Fat (g)

       

T1:

10.2

to

47.1

ALL

1

 

1

 

1

 

T2:

47.2

to

72.7

 

1.33

(0.60-2.96)

0.77

(0.43-1.38)

1.13

(0.87-1.47)

T3:

72.9

to

213.0

 

0.88

(0.29-2.66)

0.73

(0.35-1.51)

1.10

(0.74-1.63)

T1:

10.2

to

47.1

SR

1

 

1

 

1

 

T2:

47.2

to

72.7

 

1.10

(0.47-2.54)

0.67

(0.29-1.53)

1.06

(0.73-1.53)

T3:

72.9

to

213.0

 

0.81

(0.26-2.53)

0.74

(0.30-1.85)

1.11

(0.61-2.01)

Total Cholesterol (mg)

       

T1:

17.2

to

166.1

ALL

1

 

1

 

1

 

T2:

166.2

to

272.7

 

0.53

(0.24-1.14)

0.86

(0.49-1.49)

1.50*

(1.17-1.93)

T3:

273.0

to

1322.0

 

0.76

(0.31-1.86)

0.49*

(0.25-0.95)

1.31

(0.97-1.78)

T1:

17.2

to

166.1

SR

1

 

1

 

1

 

T2:

166.2

to

272.7

 

0.59

(0.25-1.41)

1.04

(0.53-2.03)

1.39

(0.98-1.97)

T3:

273.0

to

1322.0

 

1.00

(0.38-2.59)

0.68

(0.28-1.63)

1.13

(0.71-1.80)

adjusted for reporting status (all cases vs self reported cases only), age at diagnosis (<48,48-65,>65), treatment (radiation, chemo, surgery - yes/no), education (<12, 12, >12), marital status (yes/no), total calories (continuous), pack years (median = 18.5), and age at first alcoholic drink (<18,18-20,>20).

* p < 0.05

Moderate intake of total protein (HR = 0.44, 95% CI = 0.20 to 0.95, for second tertile compared to lowest tertile, in self-reported cases only; HR = 0.40, 95% CI = 0.18 to 0.93, for second tertile compared to lowest tertile, in all cases) among Grade II patients was associated with enhanced survival; a similar result was observed among Grade IV patients with high intake of total protein. Among Grade III patients, high intake of total cholesterol, in all cases, was associated with better survival. Moderate intake of total cholesterol, in all cases, was associated with poorer survival among Grade IV patients. The only statistically significant results for Antioxidant Index were observed in Grade IV patients where the highest tertile of intake, in all cases, (HR = 1.36, 95% CI = 1.02 to 1.81) was associated with poorer survival.

Discussion

Intake of dietary antioxidants and other nutrients may be part of the risk profile associated with enhanced or diminished survival following a diagnosis of glioma. Our study results offer some insights among glioma patients diagnosed with Grade II and Grade III tumors, and possibly Grade IV tumors. Our analysis included a large glioma patient cohort recruited over a 9-year interval when treatment practices remained generally unchanged. Our study cohort is comparable to other cohorts of glioma patients in the distribution of patient and clinical characteristics such as age at diagnosis and pattern of treatment.

Although most individual antioxidant effect estimates in our analyses were not statistically significant, generally the magnitude and direction of the hazard ratios in all three histology groups was consistent across self-reported cases and all cases. Some inconsistent results, however, were observed where moderate intake of lycopene was associated with poorer survival among the self-reported cases only in both Grade II and Grade III patients. A similar result for moderate intake of alpha-carotene was observed in Grade III patients. Among these two carotenoids, lycopene has been shown to inhibit progression of prostate, breast and lung cancer cell lines [26]. However while carotenoids in general exhibit antioxidant behavior at low oxygen partial pressures (below 150 Torr), they can lose antioxidant potential and become pro-oxidant at higher pressures of oxygen [26].

Significantly enhanced survival estimates were observed for moderate intake of folate as well as total protein intake among Grade II patients; this was consistent across self-reported cases and all cases. Among Grade III patients, significantly enhanced survival occurred with high intake of vitamin E, moderate intake of formononetin, and both moderate and high intake of secoisolariciresinol in all cases. Laboratory analysis has shown that vitamin E (particularly α-tocopheryl succinate and tocopherols) inhibits the angiogenic factor, vascular endothelial growth factor (VEGF), which is induced by glioma tumors, thus having the potential to limit glioma cell proliferation [55]. Gamma-tocopherols have also been shown to decrease PKC upstream and retinoblastoma(Rb) phosphorylation downstream controlling cell cycle production in C-6 glioma cells [56]. Tedeschi-Blok et al [46] observed a chemopreventive effect for moderate intake of vitamin E and formononetin, and high intake of secoisolariciresinol in a comparison of all (not stratified by histology group) glioma cases (same cohort as current study) vs controls.

Among Grade IV patients the magnitude of the hazard ratios was generally consistent across self-reported cases and all cases. Among all Grade IV cases, a number of antioxidants and other nutrients were significantly associated with poorer survival. These included high intake of the total Antioxidant Index, vitamin C, genistein, and secoisolariciresinol; modertate intake of formononetin, matairesinol and total cholesterol; moderate and high intake of cryptoxanthin. Moderate intake of total protein was associated with significantly enhanced survival. That significant results were not observed in the self-reported cases only may indicate systematic misclassification errors attributable to proxy respondents who were not entirely accurate in recalling the case's dietary habits, or to cases that were too ill to recall their actual eating patterns with clarity. The hazard ratios for secoisolariciresinol and formononetin in the Grade IV group are in the opposite direction from the corresponding hazard ratios estimated among Grade II and Grade II patients. While such difference could be due to chance, it does highlight the need for stratifying data analyses by histology group, which is a strength of the current study. Moreover, histology Grades III and IV have shorter survival following diagnosis of glioma than Grade II; and Grade IV, which has almost 100% mortality within 5 years of diagnosis, is also distinguished from Grade III. Therefore, the diet prior to diagnosis is closer to time of death for higher than lower Grade glioma patients.

The difference in the associations between antioxidants and survival of patients with different glioma grades may be explained by the specific tumor biology, differences in the interaction between the treatment and antioxidants, or by chance. There are several indications that the detected associations can not be explained by chance alone. Where the same antioxidant\nutrient was significant in more than one grade, the hazard ratios were generally in the same direction in several instances: one example is the association with lycopene among Grade II and Grade III patients; another example is total protein in Grade II and Grade IV patients.

Statistically significant results were not confined to one particular subclass of antioxidants, but were found among isoflavones (e.g. genistein), carotenoids (e.g. lycopene), lignans (e.g. matairesinol), vitamin C, vitamin E and folate. Our study also observed significant results among both fat- and water- soluble antioxidants.

Our study used patients' responses to a diet questionnaire as the primary data source for converting this information into grams of specific antioxidant consumed per day by applying an appropriate algorithm. We recognize that internal exposure dose (usually measured as plasma concentration) to antioxidants may be confounded by individual difference in absorption. However, at least for carotinoids, a correlation has been demonstrated between questionnaire-derived intake and plasma levels [57, 58].

Recent developments in treatment of malignant gliomas have provided some extension of survival time through the concomitant administration of temozolomide (TMZ) chemotherapy following surgery and radiotherapy [59]. Since our study cohort preceded the widespread introduction of TMZ as standard of care for glioblastoma (grade IV) in 2005, the enhanced survival associated with TMZ use is not reflected in this patient cohort. However a strength of our study is that the association between dietary antioxidants and glioma patient survival is not confounded by patients receiving TMZ.

Given the large number of associations examined, we acknowledge that some findings may be merely due to chance. Although there remains controversy regarding the use of some adjustment for multiple associations or comparisons in observational studies (e.g. Bonferroni), it is our position not to use them. We base our decision in part on the rationale outlined by Rothman [60] and Savitz [61]. Rothman asserts that the adjustment, while decreasing type I error, would increase the risk of type II error for associations that are not null. He furthermore states that "a policy of not making adjustment for multiple comparisons is preferable because it will lead to fewer errors of interpretation when the data under evaluation are not random numbers but actual observations on nature". As recommended, we have made clear the number and nature of statistical tests, allowing audiences their own interpretation of study findings.

Conclusions

The associations observed in our study suggest that the influence of some non-enzymatic antioxidants on survival following a diagnosis of malignant glioma are inconsistent and vary by histology group. In the same cohort of glioma patients, a case-control study found a number of significant inverse associations between antioxidant intake and gliomagenesis [46]; however our current study of antioxidant intake and glioma survival did not observe the same number of inverse associations. Further research in a large sample of glioma patients is needed to confirm or refute our study results.

Notes

Declarations

Acknowledgements

Funding has been provided by NIH grants R01CA52689 and UCSF Brain Tumor SPORE, P50CA097257, as well as by grants from the National Brain Tumor Foundation, the UCSF Lewis Chair in Brain Tumor Research and by donations from families and friends of John Berardi, Helen Glaser and Elvera Olsen. The San Francisco Adult Glioma Study thanks the Northern California Cancer Center for glioma patient case finding; we also thank Tarik Tihan and Kenneth Aldape for pathology review and the pathology departments of Alexian, Alta Bates, Brookside, California Pacific, Doctors Pinole, Eden, El Camino, Good Samaritan, Highland, John Muir, Kaiser Redwood City, Kaiser San Francisco, Kaiser Santa Teresa, Los Gatos, Los Medanos, Marin General, Merrithew, Mills Peninsula, Mt. Diablo Hospital, Mt. Zion, Naval Hospital, O'Connor, Ralph K Davies , Saint Louise, San Francisco General, San Jose, San Leandro, San Mateo County, San Ramon Valley, Santa Clara Valley, Sequoia, Seton, St. Francis, St. Luke's, St. Rose, Stanford, Summit, UC San Francisco, Valley Livermore, Veterans Palo Alto, Veterans SF, and Washington Hospitals and Medical Centers for providing tumor specimens for review.

Authors’ Affiliations

(1)
Division of Research, Kaiser Permanente Northern California
(2)
Department of Neurological Surgery, University of California San Francisco
(3)
Department of Community and Family Medicine, Duke University Medical Center

References

  1. Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, et al: Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol. 2006, 8: 12-26. 10.1215/S1522851705000268.PubMed CentralView ArticlePubMed
  2. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002, 4: 278-299. 10.1215/15228517-4-4-278.PubMed CentralPubMed
  3. Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML: The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999, 85: 485-491. 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L.View ArticlePubMed
  4. Nakamura M, Konishi N, Tsunoda S, Nakase H, Tsuzuki T, Aoki H, et al: Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology. 2000, 58: 108-116. 10.1159/000012087.View ArticlePubMed
  5. Kiwit JC, Floeth FW, Bock WJ: Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir. 1996, 57: 76-88.PubMed
  6. Ramnarayan R, Dodd S, Das K, Heidecke V, Rainov NG: Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter. J Neurol Sci. 2007, 260: 49-56. 10.1016/j.jns.2007.04.003.View ArticlePubMed
  7. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998, 90: 1473-1479. 10.1093/jnci/90.19.1473.View ArticlePubMed
  8. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, et al: Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE. 2007, 2: e576-10.1371/journal.pone.0000576.PubMed CentralView ArticlePubMed
  9. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, et al: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 2000, 92: 983-990. 10.3171/jns.2000.92.6.0983.View ArticlePubMed
  10. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M, et al: Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res. 2004, 64: 2496-2501. 10.1158/0008-5472.CAN-03-1254.View ArticlePubMed
  11. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002, 62: 3729-3735.PubMed
  12. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, et al: Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res. 2006, 66: 4531-4541. 10.1158/0008-5472.CAN-05-4032.View ArticlePubMed
  13. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, et al: Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res. 2006, 66: 4531-4541. 10.1158/0008-5472.CAN-05-4032.View ArticlePubMed
  14. Durmaz R, Vural M, Isildi E, Cosan E, Ozkara E, Bal C, et al: Efficacy of Prognostic Factors on Survival in Patients with Low Grade Glioma. Turk Neurosurg. 2008, 18: 336-344.PubMed
  15. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003, 99: 467-473. 10.3171/jns.2003.99.3.0467.View ArticlePubMed
  16. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al: Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999, 45: 923-929. 10.1016/S0360-3016(99)00284-9.View ArticlePubMed
  17. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V, et al: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol. 1997, 35: 13-28. 10.1023/A:1005841520514.View ArticlePubMed
  18. Murray KJ, Nelson DF, Scott C, Fischbach AJ, Porter A, Farnan N, et al: Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiat Oncol Biol Phys. 1995, 31: 453-459. 10.1016/0360-3016(95)93160-9.View ArticlePubMed
  19. Curran WJ, Scott CB, Weinstein AS, Martin LA, Nelson JS, Phillips TL, et al: Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol. 1993, 11: 857-862.PubMed
  20. Phuphanich S, Ferrall S, Greenberg H: Long-term survival in malignant glioma. Prognostic factors. J Fla Med Assoc. 1993, 80: 181-184.PubMed
  21. Il'yasova D, Marcello JE, McCoy L, Rice T, Wrensch M: Total dietary antioxidant index and survival in patients with glioblastoma multiforme. Cancer Causes Control. 2009, 20 (8): 1255-60. 10.1007/s10552-009-9338-7.PubMed CentralView ArticlePubMed
  22. Jarvela S, Bragge H, Paunu N, Jarvela T, Paljarvi L, Kalimo H, et al: Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol. 2006, 77: 131-140. 10.1007/s11060-006-9118-0.View ArticlePubMed
  23. Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002, 420: 860-867. 10.1038/nature01322.PubMed CentralView ArticlePubMed
  24. Stadtman ER, Levine RL: Protein oxidation. Ann N Y Acad Sci. 2000, 899: 191-208. 10.1111/j.1749-6632.2000.tb06187.x.View ArticlePubMed
  25. Ames BN, Gold LS, Willett WC: The causes and prevention of cancer. Proc Natl Acad Sci USA. 1995, 92: 5258-5265. 10.1073/pnas.92.12.5258.PubMed CentralView ArticlePubMed
  26. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006, 160: 1-40. 10.1016/j.cbi.2005.12.009.View ArticlePubMed
  27. Aeder SE, Martin PM, Soh JW, Hussaini IM: PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene. 2004, 23: 9062-9069. 10.1038/sj.onc.1208093.View ArticlePubMed
  28. da Rocha AB, Mans DR, Regner A, Schwartsmann G: Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?. Oncologist. 2002, 7: 17-33. 10.1634/theoncologist.7-1-17.View ArticlePubMed
  29. Martin V, Herrera F, Garcia-Santos G, Antolin I, Rodriguez-Blanco J, Rodriguez C: Signaling pathways involved in antioxidant control of glioma cell proliferation. Free Radic Biol Med. 2007, 42: 1715-1722. 10.1016/j.freeradbiomed.2007.02.028.View ArticlePubMed
  30. Uht RM, Amos S, Martin PM, Riggan AE, Hussaini IM: The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene. 2007, 26: 2885-2893. 10.1038/sj.onc.1210090.View ArticlePubMed
  31. Tanriverdi T, Hanimoglu H, Kacira T, Sanus GZ, Kemerdere R, Atukeren P, et al: Glutathione peroxidase, glutathione reductase and protein oxidation in patients with glioblastoma multiforme and transitional meningioma. J Cancer Res Clin Oncol. 2007, 133: 627-633. 10.1007/s00432-007-0212-2.View ArticlePubMed
  32. Smith-Pearson PS, Kooshki M, Spitz DR, Poole LB, Zhao W, Robbins ME: Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H(2)O(2). Free Radic Biol Med. 2008, 45: 1178-1189. 10.1016/j.freeradbiomed.2008.07.015.PubMed CentralView ArticlePubMed
  33. Preuss M, Girnun GD, Darby CJ, Khoo N, Spector AA, Robbins ME: Role of antioxidant enzyme expression in the selective cytotoxic response of glioma cells to gamma-linolenic acid supplementation. Free Radic Biol Med. 2000, 28: 1143-1156. 10.1016/S0891-5849(00)00210-0.View ArticlePubMed
  34. D'Archivio M, Santangelo C, Scazzocchio B, Vari R, Filesi C, Masella R, et al: Modulatory effects of polyphenols on apoptosis induction: relevance for cancer prevention. Int J Mol Sci. 2008, 9: 213-228. 10.3390/ijms9030213.PubMed CentralView ArticlePubMed
  35. Khoshyomn S, Nathan D, Manske GC, Osler TM, Penar PL: Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. J Neurooncol. 2002, 57: 193-200. 10.1023/A:1015765616484.View ArticlePubMed
  36. Pouliquen D, Olivier C, Hervouet E, Pedelaborde F, Debien E, Le Cabellec MT, et al: Dietary prevention of malignant glioma aggressiveness, implications in oxidant stress and apoptosis. Int J Cancer. 2008, 123: 288-295. 10.1002/ijc.23513.View ArticlePubMed
  37. Galati G, O'Brien PJ: Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med. 2004, 37: 287-303. 10.1016/j.freeradbiomed.2004.04.034.View ArticlePubMed
  38. Meyer F, Bairati I, Fortin A, Gelinas M, Nabid A, Brochet F, et al: Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer. 2008, 122: 1679-1683. 10.1002/ijc.23200.View ArticlePubMed
  39. Conklin KA: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004, 3: 294-300. 10.1177/1534735404270335.View ArticlePubMed
  40. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?. J Natl Cancer Inst. 2008, 100: 773-783. 10.1093/jnci/djn148.View ArticlePubMed
  41. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M: History of allergies among adults with glioma and controls. Int J Cancer. 2002, 98: 609-615. 10.1002/ijc.10239.View ArticlePubMed
  42. Wrensch M, Lee M, Miike R, Newman B, Barger G, Davis R, et al: Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol. 1997, 145: 581-593.View ArticlePubMed
  43. Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G, et al: Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer. 2000, 88: 2342-2349. 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X.View ArticlePubMed
  44. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol. 1993, 3: 255-268. 10.1111/j.1750-3639.1993.tb00752.x.View ArticlePubMed
  45. Lee M, Wrensch M, Miike R: Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control. 1997, 8: 13-24. 10.1023/A:1018470802969.View ArticlePubMed
  46. Tedeschi-Blok N, Lee M, Sison JD, Miike R, Wrensch M: Inverse association of antioxidant and phytoestrogen nutrient intake with adult glioma in the San Francisco Bay Area: a case-control study. BMC Cancer. 2006, 6: 148-10.1186/1471-2407-6-148.PubMed CentralView ArticlePubMed
  47. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L: A data-based approach to diet questionnaire design and testing. Am J Epidemiol. 1986, 124: 453-469.PubMed
  48. Preston-Martin S, Mack W: Gliomas and meningiomas in men in Los Angeles County: investigation of exposures to N-nitroso compounds. IARC Sci Publ. 1991, 197-203.
  49. Rice-Evans CA, Miller NJ: Antioxidant activities of flavonoids as bioactive components of food. Biochem Soc Trans. 1996, 24: 790-795.View ArticlePubMed
  50. Cao G, Sofic E, Prior R: Antioxidant Capapcity of Tea and Common Vegetables. J Agric Food Chem. 1996, 44: 3426-3431. 10.1021/jf9602535.View Article
  51. Wang H, Cao G, Prior R: Total Antioxidant Capacity of Fruits. J Agric Food Chem. 1996, 44: 701-705. 10.1021/jf950579y.View Article
  52. Nordmann R: Oxidative stress from alcohol in the brain. Alcohol Alcohol Suppl. 1987, 1: 75-82.PubMed
  53. Preston AM: Cigarette smoking-nutritional implications. Prog Food Nutr Sci. 1991, 15: 183-217.PubMed
  54. Phuphanich S, Ferrall S, Greenberg H: Long-term survival in malignant glioma. Prognostic factors. J Fla Med Assoc. 1993, 80: 181-184.PubMed
  55. Schindler R, Mentlein R: Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J Nutr. 2006, 136: 1477-1482.PubMed
  56. Betti M, Minelli A, Canonico B, Castaldo P, Magi S, Aisa MC, et al: Antiproliferative effects of tocopherols (vitamin E) on murine glioma C6 cells: homologue-specific control of PKC/ERK and cyclin signaling. Free Radic Biol Med. 2006, 41: 464-472. 10.1016/j.freeradbiomed.2006.04.012.View ArticlePubMed
  57. Al Delaimy WK, Ferrari P, Slimani N, Pala V, Johansson I, Nilsson S, et al: Plasma carotenoids as biomarkers of intake of fruits and vegetables: individual-level correlations in the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Clin Nutr. 2005, 59: 1387-1396. 10.1038/sj.ejcn.1602252.View ArticlePubMed
  58. Hodge AM, Simpson JA, Fridman M, Rowley K, English DR, Giles GG, et al: Evaluation of an FFQ for assessment of antioxidant intake using plasma biomarkers in an ethnically diverse population. Public Health Nutr. 2009, 12: 2438-2447. 10.1017/S1368980009005539.View ArticlePubMed
  59. Stupp R, Mason WP, Bent van den MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330.View ArticlePubMed
  60. Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology. 1990, 1: 43-46. 10.1097/00001648-199001000-00010.View ArticlePubMed
  61. Savitz DA: . Interpreting Epidemiologic Evidence: Strategies for Study Design and Analysis. 2003, New York: Oxford University Press
  62. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2407/​10/​215/​prepub

Copyright

© DeLorenze et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement